Evaluation of Serum Procalcitonin in Critically Ill Patients With Suspected Sepsis
NCT ID: NCT03506152
Last Updated: 2018-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
103 participants
OBSERVATIONAL
2014-01-01
2015-12-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
NCT04105400
Use of Procalcitonin, a Blood Test to Guide Antibiotic Therapy for Sepsis in Adults
NCT05955612
Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit
NCT01085994
A Clinical Trial of Procalcitonin-guided Antimicrobial Therapy in Sepsis
NCT03333304
Procalcitonin and Antimicrobial Utilization in Critically Ill Cancer Patients with Sepsis
NCT04203524
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Material and Methods: A cross-sectional study conducted at section of Chemical Pathology, Department of Pathology and Laboratory Medicine and ICU. Patients with suspected sepsis were included, serum PCT cut off ≥0.5 ng /ml was taken for diagnosing sepsis. Diagnostic accuracy was measured in terms of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) taking blood culture as gold standard. Furthermore, different cut offs were compared by using receiver operating characteristic curves (ROC). Data analysis was done on SPSS version.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Culture positive
Serum Procalcitonin
Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
Culture negative
Serum Procalcitonin
Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum Procalcitonin
Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients full filling the sepsis definition (American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference)
3. Patients were recruited within 24 hour of ICU admission
Exclusion Criteria
2. Patients who had blood transfusion before ICU stay
3. Patients with organ failure
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aga Khan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sibtain Ahmed
Consultant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sibtain Ahmed
Karachi, Sindh, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RRG # 2013-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.